Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes

Yuan, Zixuan; Zhao, Liang; Zhang, Yafei; Li, Shun; Pan, Bomin; Liu, Hua; Wang, Zhen; Ye, Chengkun; Lü, Jun; Yu, Rutong; Liu, Hongmei

doi:10.1007/s11060-018-2966-6

Cited by 20 publications

(13 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Actually, in the last 2 years, some authors reported on this topic. Yuan and collaborators [73] targeted GOLPH3 through siRNA loaded on cationic liposomes, obtaining the inhibition of glioma growth in vivo, in a nude mouse model. A similar nanoparticle-mediated approach was used by Ye and co-workers, who co-delivered GOLPH3 siRNA and gefitinib (Ge, an anti-EGFR drug) in vitro (U87 and T98G glioma cell lines) and in vivo (BALB/c nude mice), obtaining growth inhibition and apoptosis induction [74].…”

Section: Golph3 Deregulation and Brain Tumorsmentioning

confidence: 99%

Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer

Sechi

Frappaolo

Karimpour-Ghahnavieh

et al. 2020

IJMS

View full text Add to dashboard Cite

Golgi phosphoprotein 3 (GOLPH3), a Phosphatidylinositol 4-Phosphate [PI(4)P] effector at the Golgi, is required for Golgi ribbon structure maintenance, vesicle trafficking and Golgi glycosylation. GOLPH3 has been validated as an oncoprotein through combining integrative genomics with clinopathological and functional analyses. It is frequently amplified in several solid tumor types including melanoma, lung cancer, breast cancer, glioma, and colorectal cancer. Overexpression of GOLPH3 correlates with poor prognosis in multiple tumor types including 52% of breast cancers and 41% to 53% of glioblastoma. Roles of GOLPH3 in tumorigenesis may correlate with several cellular activities including: (i) regulating Golgi-to-plasma membrane trafficking and contributing to malignant secretory phenotypes; (ii) controlling the internalization and recycling of key signaling molecules or increasing the glycosylation of cancer relevant glycoproteins; and (iii) influencing the DNA damage response and maintenance of genomic stability. Here we summarize current knowledge on the oncogenic pathways involving GOLPH3 in human cancer, GOLPH3 influence on tumor metabolism and surrounding stroma, and its possible role in tumor metastasis formation.

show abstract

Section: Golph3 Deregulation and Brain Tumorsmentioning

confidence: 99%

Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer

Sechi

Frappaolo

Karimpour-Ghahnavieh

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…In addition to chemotherapy, immunotherapies, such as CAR-T [ 68 , 69 , 70 , 71 ] and immune checkpoint inhibitors of cytotoxic T lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 (PD-1), and programmed cell death protein 1 ligand (PD-L1) [ 72 , 73 , 74 ], have been recently investigated for GBM treatment. Moreover, induced pluripotent stem cell-based regenerative medicine [ 75 ] and gene therapies (adenovirus, herpes simplex virus-1, retrovirus, shRNA, siRNA, non-viral vectors) have been developed and evaluated [ 76 , 77 , 78 , 79 ]. We will evaluate the combination of our mAb-EV-Ver-A and immunotherapy or gene therapy for GBM treatment in the future.…”

Section: Discussionmentioning

confidence: 99%

Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma

Chen

Guan

et al. 2022

Biomedicines

View full text Add to dashboard Cite

Glioblastomas, accounting for approximately 50% of gliomas, comprise the most aggressive, highly heterogeneous, and malignant brain tumors. The objective of this study was to develop and evaluate a new targeted therapy, i.e., highly potent natural compound verrucarin A (Ver-A), delivered with monoclonal antibody-directed extracellular vesicle (mAb-EV). First, the high surface expression of epidermal growth factor receptor (EGFR) in glioblastoma patient tissue and cell lines was confirmed using immunohistochemistry staining, flow cytometry, and Western blotting. mAb-EV-Ver-A was constructed by packing Ver-A and tagging anti-EGFR mAb to EV generated from HEK293F culture. Confocal microscopy and the In Vivo Imaging System demonstrated that mAb-EV could penetrate the blood–brain barrier, target intracranial glioblastoma xenografts, and deliver drug intracellularly. The in vitro cytotoxicity study showed IC50 values of 2–12 nM of Ver-A. The hematoxylin and eosin staining of major organs in the tolerated dose study indicated minimal systemic toxicity of mAb-EV-Ver-A. Finally, the in vivo anti-tumor efficacy study in intracranial xenograft models demonstrated that EGFR mAb-EV-Ver-A effectively inhibited glioblastoma growth, but the combination with VEGF mAb did not improve the therapeutic efficacy. This study suggested that mAb-EV is an effective drug delivery vehicle and natural Ver-A has great potential to treat glioblastoma.

show abstract

“…Conveniently, cationic liposomes are amenable to carrying both drugs and genes [30]. Angiopep-2-functionalized cationic liposomes were shown to effectively deliver siRNA against Golgi phosphoprotein 3 (GOLPH3) specifically to glioma and inhibit its growth in U87-GFP-Luci-bearing BALB/c mouse models [31].…”

Section: Angiopep-2-decorated Nanoparticlesmentioning

confidence: 99%

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Habib

Singh

2022

Polymers

View full text Add to dashboard Cite

Nanotechnology has opened up a world of possibilities for the treatment of brain disorders. Nanosystems can be designed to encapsulate, carry, and deliver a variety of therapeutic agents, including drugs and nucleic acids. Nanoparticles may also be formulated to contain photosensitizers or, on their own, serve as photothermal conversion agents for phototherapy. Furthermore, nano-delivery agents can enhance the efficacy of contrast agents for improved brain imaging and diagnostics. However, effective nano-delivery to the brain is seriously hampered by the formidable blood–brain barrier (BBB). Advances in understanding natural transport routes across the BBB have led to receptor-mediated transcytosis being exploited as a possible means of nanoparticle uptake. In this regard, the oligopeptide Angiopep-2, which has high BBB transcytosis capacity, has been utilized as a targeting ligand. Various organic and inorganic nanostructures have been functionalized with Angiopep-2 to direct therapeutic and diagnostic agents to the brain. Not only have these shown great promise in the treatment and diagnosis of brain cancer but they have also been investigated for the treatment of brain injury, stroke, epilepsy, Parkinson’s disease, and Alzheimer’s disease. This review focuses on studies conducted from 2010 to 2021 with Angiopep-2-modified nanoparticles aimed at the treatment and diagnosis of brain disorders.

show abstract

Inhibition of glioma growth by a GOLPH3 siRNA-loaded cationic liposomes

Abstract: This study shows that GOLPH3 has great potential as a target for the gene therapy of glioma and is of great value in precise medical applications.

Cited by 20 publications

References 27 publications

Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer

Oncogenic Roles of GOLPH3 in the Physiopathology of Cancer

Targeted Extracellular Vesicles Delivered Verrucarin A to Treat Glioblastoma

Angiopep-2-Modified Nanoparticles for Brain-Directed Delivery of Therapeutics: A Review

Contact Info

Product

Resources

About